Fig. 1

Trial profile. HETROM-2.5, the dose was titrated from an initial dosage of once-daily 2.5 mg hetrombopag; HETROM-5, the dose was titrated from an initial dosage of once-daily 5 mg hetrombopag; AEs, adverse events. *Eligible patients were randomly allocated at a ratio of 4:4:1:1 to the HETROM-2.5 group, the HETROM-5 group, and matching placebo groups. The two matching placebo groups were pooled as the Placebo group